Article Details
Retrieved on: 2018-06-02 17:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>As Pfizer (PFE) Valuation Declined, Insight 2811 Has Boosted Position by $403,725; <b>Crosslink Capital</b> Holding in Interxion (INXN) Has Trimmed as ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here